본문 바로가기

Report

All 3,239,921 Page 46/323,993

검색
  • 2025


    • Book : 211()
    • Pub. Date : 2025
    • Page : pp.110942
    • Keyword :
  • 2025


    • Book : 603()
    • Pub. Date : 2025
    • Page : pp.155404
    • Keyword :
  • 2025


    • Book : 603()
    • Pub. Date : 2025
    • Page : pp.155398
    • Keyword :
  • 2025


    • Book : 245()
    • Pub. Date : 2025
    • Page : pp.114220
    • Keyword :
  • 2025


    • Book : 211()
    • Pub. Date : 2025
    • Page : pp.110973
    • Keyword :
  • 2025

    Approximately 20 million new instances of cancer and 10 million cancer-related deaths were reported in 2023, making cancer one of the leading causes of mortality globally. The number of deaths due to cancer worldwide is expected to double by 2050 to an estimated 18.5 million, compared to 9.7 million in 2022. Though there are heaps of new advanced techniques and therapies present for the treatment or control of cancer exist; however, complete treatment is not yet available. Chemotherapy and radiation-based therapy are examples of cancer treatments that function by eradicating or damaging cancer cells, which may sometimes negatively affect as well as harm normal cells throughout the process. Phyto-pharmaceuticals have shown promising results in the management of cancer due to potential anticancer efficacy. There is a large variety of medicinal herbs that exhibit anticancer properties; however, few are known and not yet evaluated in humans. Recently these bioactive compounds were combined with modified medications driven by nanotechnology (NT), and drug delivery systems are being fabricated and commercialized to improve the management of cancer with positive results. Drug delivery to cancer cells can be made more effective using nano-carriers with prolong medication half-lives, improve solubility and stability, and lessen side effects in organs other than the target. The review focuses on a new nano-enabled approach to delivering the medication that leverages bioactive compounds in either entrapped or tagged to carriers. Additionally, the review provides a sense of the obstacles and constraints associated with conventional cancer therapy, as well as the bioavailability of bioactive compounds.


    • Book : 15(4)
    • Pub. Date : 2025
    • Page : pp.2430006
    • Keyword :
  • 2025


    • Book : 123()
    • Pub. Date : 2025
    • Page : pp.1052-1060
    • Keyword :
  • 2025


    • Book : 288(1)
    • Pub. Date : 2025
    • Page : pp.110670
    • Keyword :
  • 2025


    • Book : ()
    • Pub. Date : 2025
    • Page :
    • Keyword :
  • 2025

    Astrocytes are the most abundant type of glial cell in the central nervous system. Upon injury and inflammation, astrocytes become reactive and undergo morphological and functional changes. Depending on their phenotypic classification as A1 or A2, reactive astrocytes contribute to both neurotoxic and neuroprotective responses, respectively. However, this binary classification does not fully capture the diversity of astrocyte responses observed across different diseases and injuries. Transcriptomic analysis has revealed that reactive astrocytes have a complex landscape of gene expression profiles, which emphasizes the heterogeneous nature of their reactivity. Astrocytes actively participate in regulating central nervous system inflammation by interacting with microglia and other cell types, releasing cytokines, and influencing the immune response. The phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway is a central player in astrocyte reactivity and impacts various aspects of astrocyte behavior, as evidenced by in silico, in vitro, and in vivo results. In astrocytes, inflammatory cues trigger a cascade of molecular events, where nuclear factor-κB serves as a central mediator of the pro-inflammatory responses. Here, we review the heterogeneity of reactive astrocytes and the molecular mechanisms underlying their activation. We highlight the involvement of various signaling pathways that regulate astrocyte reactivity, including the PI3K/AKT/mammalian target of rapamycin (mTOR), αvβ3 integrin/PI3K/AKT/connexin 43, and Notch/PI3K/AKT pathways. While targeting the inactivation of the PI3K/AKT cellular signaling pathway to control reactive astrocytes and prevent central nervous system damage, evidence suggests that activating this pathway could also yield beneficial outcomes. This dual function of the PI3K/AKT pathway underscores its complexity in astrocyte reactivity and brain function modulation. The review emphasizes the importance of employing astrocyte-exclusive models to understand their functions accurately and these models are essential for clarifying astrocyte behavior. The findings should then be validated using in vivo models to ensure real-life relevance. The review also highlights the significance of PI3K/AKT pathway modulation in preventing central nervous system damage, although further studies are required to fully comprehend its role due to varying factors such as different cell types, astrocyte responses to inflammation, and disease contexts. Specific strategies are clearly necessary to address these variables effectively.


    • Book : 20(4)
    • Pub. Date : 2025
    • Page : pp.1031-1041
    • Keyword :